Tempted by the AstraZeneca share price? Here’s why it could explode in 2023

The AstraZeneca share price has more than doubled over five years. Our writer outlines why the FTSE 100 healthcare stock could climb even higher in 2023.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past half-decade, the AstraZeneca (LSE: AZN) share price outperformed all FTSE 100 stocks bar one. Blistering 119% growth over five years means the biotech company’s shares trade for £111.77 each as I write — a huge gain from £50.95 in January 2018.

Even after explosive growth, I believe the Anglo-Swedish pharmaceutical giant still has plenty of upside potential today. As a shareholder, I’m hopeful this potential translates into positive movement for the share price.

Here’s my take on the business and why I’m buying more AstraZeneca shares in 2023.

Company-specific reasons

First, let’s look at AstraZeneca’s pipeline. The company has 179 projects on the go. This includes 13 new molecular entities in its late-stage pipeline and two recent approvals. In my view, the business has one of the most promising portfolios of any pharma company globally.

Although Covid vaccines made the firm a household name, its strength runs far deeper. AstraZeneca’s medicines cover an array of healthcare issues from oncology to cardiovascular disease and respiratory illnesses.

The company’s also expanding. It recently took advantage of a crash in the CinCor Pharma share price to snap up the blood pressure biotech outfit. The deal will be worth $1.8bn if Cincor can secure regulatory approval for its baxdrostat product for patients with treatment-resistant hypertension.

The drug can potentially be combined with AstraZeneca’s Farxiga medication to address cardiorenal disease, which could contribute significantly to the firm’s revenue. The merger agreement’s expected to conclude in first quarter of 2023, if all conditions are met.

Source: AstraZeneca Q3 2022 Results Presentation

Beyond a strong pipeline and ambitious expansion plans, another reason I like AstraZeneca is the geographic diversification it offers. With truly global sources of revenue, the company’s not overly exposed to any single global region in my view.

There are also macroeconomic factors that make the pharmaceutical industry an attractive play for me at present. No firm is immune to the scourge of high inflation, but pharma companies have high levels of discretionary spending and considerable pricing power.

What’s more, the industry’s relatively non-cyclical. Whether the economy’s performing well or in a downturn, demand for medicines remains fairly constant. As possible recessions loom, I’m keen to boost my exposure to the sector to hedge against potential falls in the value of my other investments.

Risks

Admittedly, there are risks that could derail the stock’s positive trajectory. The business has a high price-to-earnings (P/E) ratio over 105, which suggests it’s expensive using traditional valuation metrics.

There’s also the concern that some candidate drugs might fail to secure regulatory approval. This could weigh on expected earnings growth and hurt the AstraZeneca share price in the process.

It’s a tricky balancing act. If there aren’t enough new approvals to replace patent expiries in the coming years, the promising outlook for the business could change.

Why I’m buying more AstraZeneca shares

Despite concerns over a high P/E ratio, I believe a premier pipeline warrants a premium valuation. AstraZeneca’s at the forefront of ground-breaking advances in the medical field. I think the company’s well positioned to continue its outperformance among FTSE 100 shares.

A promising combination of micro and macro factors make me bullish on AstraZeneca. I’ll be buying more this week.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has positions in AstraZeneca Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »